Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay
3+ hour, 55+ min ago (282+ words) FDA has granted Emergency Use Authorization to Seegene USA's Allplex multiplex PCR assay, making it the first U.S.-authorized test to simultaneously detect and differentiate HSV-1, HSV-2, VZV, and monkeypox virus in a single reaction. Seegene USA, the U.S. subsidiary of molecular…...
What Policy Tools Move the Needle on API Manufacturing Capacity?
6+ hour, 26+ min ago (212+ words) Pharmaceutical Executive He characterizes the policy environment as notably bipartisan, with agreement across both political parties and the last administrations on several core principles: the United States needs better visibility into critical medicines, more secure domestic capacity for those products,…...
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
8+ hour, 25+ min ago (694+ words) The catalyst for this renewed interest is the USPTO Appeals Review Panel's Ex parte Chamberlain decision and the Federal Circuit decision on appeal. In 2023, the U.S. Supreme Court invalidated a pharma company’s broad functional patent claims and set important precedent in…...
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
8+ hour, 25+ min ago (1259+ words) Nuvation Bio’s president, CEO, and founder discusses the company’s mission, approach to developing a global strategy, and how it manages its increasing pipeline. Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is…...
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
8+ hour, 27+ min ago (323+ words) Dr. Gurinder S. Sidhu, senior medical director and U.S. Antiviral Medical Lead, Pfizer, discusses how Covid-19 remains a serious threat to the roughly 75% of American adults who qualify as high-risk, and pushes back against clinician complacency. In a conversation with Pharmaceutical Executive,…...
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
1+ day, 36+ min ago (533+ words) In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI…...
FDA Clears Consano’s IND for C-1101
1+ day, 3+ hour ago (432+ words) Pharmaceutical Executive Consano Bio received FDA clearance of its investigational new drug application for C-1101, its lead therapy for chronic lumbosacral radiculopathy, commonly known as chronic sciatica The clearance authorizes expansion of Consano's Phase I clinical trial to U.S sites, complementing…...
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
1+ day, 3+ hour ago (426+ words) Bristol Myers Squibb is deploying Nvidia's DGX SuperPOD with Vera Rubin NVL72 systems to build what it claims is the most powerful AI computing infrastructure in life sciences. Bristol Myers Squibb (BMS) announced an expansion of its compute infrastructure through the…...
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
1+ day, 12+ hour ago (443+ words) Robert Allen, Ph.D., Chief Scientific Officer, outlines how the company's Invymab platform uses viral surveillance and predictive modeling to design monoclonal antibodies against likely future variants rather than current strains. In a conversation with Pharmaceutical Executive, Robert Allen, Ph.D., chief…...
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
1+ day, 8+ hour ago (217+ words) Pharmaceutical Executive Gerren McHam, vice president of Government and External Affairs, API Innovation Center, describes how Chinaâs recent export control updates may introduce new vulnerabilities for the U.S He frames the discussion around two new regulations that together…...